Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 31;70(4):501-508.
doi: 10.33549/physiolres.934618. Epub 2021 Jun 1.

The role of AMPK/mTOR signaling pathway in anticancer activity of metformin

Affiliations
Review

The role of AMPK/mTOR signaling pathway in anticancer activity of metformin

N Chomanicova et al. Physiol Res. .

Abstract

Metformin (MTF) is a widely used drug for the treatment of diabetes mellitus type 2 (DM2) and frequently used as an adjuvant therapy for polycystic ovarian syndrome, metabolic syndrome, and in some cases also tuberculosis. Its protective effect on the cardiovascular system has also been described. Recently, MTF was subjected to various analyzes and studies that showed its beneficial effects in cancer treatment such as reducing cancer cell proliferation, reducing tumor growth, inducing apoptosis, reducing cancer risk in diabetic patients, or reducing likelihood of relapse. One of the MTF's mechanisms of action is the activation of adenosine-monophosphate-activated protein kinase (AMPK). Several studies have shown that AMPK/mammalian target of rapamycin (mTOR) pathway has anticancer effect in vivo and in vitro. The aim of this review is to present the anticancer activity of MTF highlighting the importance of the AMPK/mTOR pathway in the cancer process.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

There is no conflict of interest.

Figures

Fig. 1
Fig. 1
The various diseases where MTF has a beneficial effect.
Fig. 2
Fig. 2
The role of MTF in metabolism and cancer process through AMPK/mTOR signaling pathway. AMPK activation inhibits mTORC1, leading to decreasing of cell growth, angiogenesis and Warburg effect, and increasing of apoptosis. ATP adenosine-triphosphate, AMP adenosine-monophosphate, ATM ataxia telangiectasia mutated, LKB1 liver kinase B1, AMPK adenosine-monophosphate-activated protein kinase, HMG-CoA β-Hydroxy β-methylglutaryl-coenzyme-A, IGF-1 insulin-like growth factor 1, IGF-R insulin-like growth factor receptor, PI3K phosphatidylinositol-3-kinase, Akt protein kinase B, mTORC1 mammalian target of rapamycin complex 1, TSC1,2 tuberous sclerosis complex 1,2, Rheb Ras homolog enriched in brain, RAPTOR regulatory-associated protein of mTOR, mTOR mammalian target of rapamycin, p53 tumor suppressor protein, p70S6K p70S6 kinase, HIF-1α hypoxia-inducible factor 1α, VEGF vascular endothelial growth factor, BAX BCL-2 associated X protein.

Similar articles

Cited by

References

    1. ABDEL-WAHAB AF, MAHMOUD W, AL-HARIZY R. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019;150:104511. doi: 10.1016/j.phrs.2019.104511. - DOI - PubMed
    1. BLOCK KI, GYLLENHAAL C, LOWE L, AMEDEI A, AMIN ARMR, AMIN A, AQUILANO K, ARBISER J, ARREOLA A, ARZUMANYAN A, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015;35:276–304. doi: 10.1016/j.semcancer.2015.09.007. - DOI - PMC - PubMed
    1. CANTORIA MJ, PATEL H, BOROS LG, MEUILLET EJ. Pancreatic cancer-insights into molecular mechanisms and novel approaches to early detection and treatment. London, UK: IntechOpen; 2014. Metformin and pancreatic cancer metabolism. - DOI
    1. CICCARESE F, ZULATO E, INDRACCOLO S. LKB1/AMPK Pathway and drug response in cancer: A therapeutic perspective. Oxid Med Cell Longev. 2019:8730816. doi: 10.1155/2019/8730816. - DOI - PMC - PubMed
    1. DELHALLE S, DUVOIX A, SCHNEKENBURGER M, MORCEAU F, DICATO M, DIEDERICH M. An introduction to the molecular mechanisms of apoptosis. Ann NY Acad Sci. 2003;1010:1–8. doi: 10.1196/annals.1299.001. - DOI - PubMed

MeSH terms